Cargando…

A link between the fibroblast growth factor axis and the miR‐16 family reveals potential new treatment combinations in mesothelioma

Malignant pleural mesothelioma (MPM) is an aggressive malignancy with very limited therapeutic options. Fibroblast growth factor (FGF) signals play important roles in mesothelioma cell growth. Several FGFs and FGF receptors (FGFRs) are predicted targets of the miR‐15/16 family, which is downregulate...

Descripción completa

Detalles Bibliográficos
Autores principales: Schelch, Karin, Kirschner, Michaela B., Williams, Marissa, Cheng, Yuen Y., van Zandwijk, Nico, Grusch, Michael, Reid, Glen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748487/
https://www.ncbi.nlm.nih.gov/pubmed/29094504
http://dx.doi.org/10.1002/1878-0261.12150
_version_ 1783289408492929024
author Schelch, Karin
Kirschner, Michaela B.
Williams, Marissa
Cheng, Yuen Y.
van Zandwijk, Nico
Grusch, Michael
Reid, Glen
author_facet Schelch, Karin
Kirschner, Michaela B.
Williams, Marissa
Cheng, Yuen Y.
van Zandwijk, Nico
Grusch, Michael
Reid, Glen
author_sort Schelch, Karin
collection PubMed
description Malignant pleural mesothelioma (MPM) is an aggressive malignancy with very limited therapeutic options. Fibroblast growth factor (FGF) signals play important roles in mesothelioma cell growth. Several FGFs and FGF receptors (FGFRs) are predicted targets of the miR‐15/16 family, which is downregulated in MPM. The aim of this study was to explore the link between the miR‐15/16 family and the FGF axis in MPM. Expression analyses via RT‐qPCR showed downregulation of the FGF axis after transfection with miR‐15/16 mimics. Direct interaction was confirmed by luciferase reporter assays. Restoration of miR‐15/16 led to dose‐dependent growth inhibition in MPM cell lines, which significantly correlated with their sensitivity to FGFR inhibition. Treatment with recombinant FGF2 prevented growth inhibition and further reduced the levels of FGF/R‐targeting microRNAs, indicating a vicious cycle between miR‐15/16 down‐ and FGF/FGFR signaling upregulation. Combined inhibition of two independent miR‐15/16 targets, the FGF axis and Bcl‐2, resulted in additive or synergistic activity. Our data indicate that post‐transcriptional repression of FGF‐mediated signals contributes to the tumor suppressor function of the microRNA‐15/16 family. Inhibiting hyperactivated FGF signals and Bcl‐2 might serve as a novel therapeutic combination strategy in MPM.
format Online
Article
Text
id pubmed-5748487
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-57484872018-01-04 A link between the fibroblast growth factor axis and the miR‐16 family reveals potential new treatment combinations in mesothelioma Schelch, Karin Kirschner, Michaela B. Williams, Marissa Cheng, Yuen Y. van Zandwijk, Nico Grusch, Michael Reid, Glen Mol Oncol Research Articles Malignant pleural mesothelioma (MPM) is an aggressive malignancy with very limited therapeutic options. Fibroblast growth factor (FGF) signals play important roles in mesothelioma cell growth. Several FGFs and FGF receptors (FGFRs) are predicted targets of the miR‐15/16 family, which is downregulated in MPM. The aim of this study was to explore the link between the miR‐15/16 family and the FGF axis in MPM. Expression analyses via RT‐qPCR showed downregulation of the FGF axis after transfection with miR‐15/16 mimics. Direct interaction was confirmed by luciferase reporter assays. Restoration of miR‐15/16 led to dose‐dependent growth inhibition in MPM cell lines, which significantly correlated with their sensitivity to FGFR inhibition. Treatment with recombinant FGF2 prevented growth inhibition and further reduced the levels of FGF/R‐targeting microRNAs, indicating a vicious cycle between miR‐15/16 down‐ and FGF/FGFR signaling upregulation. Combined inhibition of two independent miR‐15/16 targets, the FGF axis and Bcl‐2, resulted in additive or synergistic activity. Our data indicate that post‐transcriptional repression of FGF‐mediated signals contributes to the tumor suppressor function of the microRNA‐15/16 family. Inhibiting hyperactivated FGF signals and Bcl‐2 might serve as a novel therapeutic combination strategy in MPM. John Wiley and Sons Inc. 2017-11-18 2018-01 /pmc/articles/PMC5748487/ /pubmed/29094504 http://dx.doi.org/10.1002/1878-0261.12150 Text en © 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Schelch, Karin
Kirschner, Michaela B.
Williams, Marissa
Cheng, Yuen Y.
van Zandwijk, Nico
Grusch, Michael
Reid, Glen
A link between the fibroblast growth factor axis and the miR‐16 family reveals potential new treatment combinations in mesothelioma
title A link between the fibroblast growth factor axis and the miR‐16 family reveals potential new treatment combinations in mesothelioma
title_full A link between the fibroblast growth factor axis and the miR‐16 family reveals potential new treatment combinations in mesothelioma
title_fullStr A link between the fibroblast growth factor axis and the miR‐16 family reveals potential new treatment combinations in mesothelioma
title_full_unstemmed A link between the fibroblast growth factor axis and the miR‐16 family reveals potential new treatment combinations in mesothelioma
title_short A link between the fibroblast growth factor axis and the miR‐16 family reveals potential new treatment combinations in mesothelioma
title_sort link between the fibroblast growth factor axis and the mir‐16 family reveals potential new treatment combinations in mesothelioma
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748487/
https://www.ncbi.nlm.nih.gov/pubmed/29094504
http://dx.doi.org/10.1002/1878-0261.12150
work_keys_str_mv AT schelchkarin alinkbetweenthefibroblastgrowthfactoraxisandthemir16familyrevealspotentialnewtreatmentcombinationsinmesothelioma
AT kirschnermichaelab alinkbetweenthefibroblastgrowthfactoraxisandthemir16familyrevealspotentialnewtreatmentcombinationsinmesothelioma
AT williamsmarissa alinkbetweenthefibroblastgrowthfactoraxisandthemir16familyrevealspotentialnewtreatmentcombinationsinmesothelioma
AT chengyueny alinkbetweenthefibroblastgrowthfactoraxisandthemir16familyrevealspotentialnewtreatmentcombinationsinmesothelioma
AT vanzandwijknico alinkbetweenthefibroblastgrowthfactoraxisandthemir16familyrevealspotentialnewtreatmentcombinationsinmesothelioma
AT gruschmichael alinkbetweenthefibroblastgrowthfactoraxisandthemir16familyrevealspotentialnewtreatmentcombinationsinmesothelioma
AT reidglen alinkbetweenthefibroblastgrowthfactoraxisandthemir16familyrevealspotentialnewtreatmentcombinationsinmesothelioma
AT schelchkarin linkbetweenthefibroblastgrowthfactoraxisandthemir16familyrevealspotentialnewtreatmentcombinationsinmesothelioma
AT kirschnermichaelab linkbetweenthefibroblastgrowthfactoraxisandthemir16familyrevealspotentialnewtreatmentcombinationsinmesothelioma
AT williamsmarissa linkbetweenthefibroblastgrowthfactoraxisandthemir16familyrevealspotentialnewtreatmentcombinationsinmesothelioma
AT chengyueny linkbetweenthefibroblastgrowthfactoraxisandthemir16familyrevealspotentialnewtreatmentcombinationsinmesothelioma
AT vanzandwijknico linkbetweenthefibroblastgrowthfactoraxisandthemir16familyrevealspotentialnewtreatmentcombinationsinmesothelioma
AT gruschmichael linkbetweenthefibroblastgrowthfactoraxisandthemir16familyrevealspotentialnewtreatmentcombinationsinmesothelioma
AT reidglen linkbetweenthefibroblastgrowthfactoraxisandthemir16familyrevealspotentialnewtreatmentcombinationsinmesothelioma